These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33892777)

  • 1. MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers.
    Murphy RJ; Sumner RL; Evans W; Menkes D; Lambrecht I; Ponton R; Sundram F; Hoeh N; Ram S; Reynolds L; Muthukumaraswamy S
    Trials; 2021 Apr; 22(1):302. PubMed ID: 33892777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.
    Murphy RJ; Sumner R; Evans W; Ponton R; Ram S; Godfrey K; Forsyth A; Cavadino A; Krishnamurthy Naga V; Smith T; Hoeh NR; Menkes DB; Muthukumaraswamy S
    Biol Psychiatry; 2023 Sep; 94(6):511-521. PubMed ID: 36997080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial.
    Murphy RJ; Godfrey K; Shaw AD; Muthukumaraswamy S; Sumner RL
    BMC Neurosci; 2024 Feb; 25(1):7. PubMed ID: 38317077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.
    Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H
    Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
    Anderson T; Petranker R; Rosenbaum D; Weissman CR; Dinh-Williams LA; Hui K; Hapke E; Farb NAS
    Psychopharmacology (Berl); 2019 Feb; 236(2):731-740. PubMed ID: 30604183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LSD increases sleep duration the night after microdosing.
    Allen N; Jeremiah A; Murphy R; Sumner R; Forsyth A; Hoeh N; Menkes DB; Evans W; Muthukumaraswamy S; Sundram F; Roop P
    Transl Psychiatry; 2024 Apr; 14(1):191. PubMed ID: 38622150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microdosing Psychedelics: Current Evidence From Controlled Studies.
    Murphy RJ; Muthukumaraswamy S; de Wit H
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):500-511. PubMed ID: 38280630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
    Family N; Maillet EL; Williams LTJ; Krediet E; Carhart-Harris RL; Williams TM; Nichols CD; Goble DJ; Raz S
    Psychopharmacology (Berl); 2020 Mar; 237(3):841-853. PubMed ID: 31853557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.
    Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Holze F; Liechti ME; Feilding A; Ramaekers JG; Kuypers KPC
    Eur Neuropsychopharmacol; 2020 Dec; 41():81-91. PubMed ID: 33082016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-individual variability in neural response to low doses of LSD.
    Hutten NRPW; Quaedflieg CWEM; Mason NL; Theunissen EL; Liechti ME; Duthaler U; Kuypers KPC; Bonnelle V; Feilding A; Ramaekers JG
    Transl Psychiatry; 2024 Jul; 14(1):288. PubMed ID: 39009578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants.
    Holze F; Liechti ME; Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Duthaler U; Feilding A; Ramaekers JG; Kuypers KPC
    Clin Pharmacol Ther; 2021 Mar; 109(3):658-666. PubMed ID: 32975835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention.
    Petranker R; Anderson T; Maier LJ; Barratt MJ; Ferris JA; Winstock AR
    J Psychopharmacol; 2022 Jan; 36(1):85-96. PubMed ID: 33591231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study.
    de Wit H; Molla HM; Bershad A; Bremmer M; Lee R
    Addict Biol; 2022 Mar; 27(2):e13143. PubMed ID: 35106880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
    Schmid Y; Enzler F; Gasser P; Grouzmann E; Preller KH; Vollenweider FX; Brenneisen R; Müller F; Borgwardt S; Liechti ME
    Biol Psychiatry; 2015 Oct; 78(8):544-53. PubMed ID: 25575620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults.
    Murray CH; Tare I; Perry CM; Malina M; Lee R; de Wit H
    Psychopharmacology (Berl); 2022 Jun; 239(6):1735-1747. PubMed ID: 34613430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).
    Donegan CJ; Daldegan-Bueno D; Sumner R; Menkes D; Evans W; Hoeh N; Sundram F; Reynolds L; Ponton R; Cavadino A; Smith T; Roop P; Allen N; Abeysinghe B; Svirskis D; Forsyth A; Bansal M; Muthukumaraswamy S
    Pilot Feasibility Stud; 2023 Oct; 9(1):169. PubMed ID: 37798662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic microdosing benefits and challenges: an empirical codebook.
    Anderson T; Petranker R; Christopher A; Rosenbaum D; Weissman C; Dinh-Williams LA; Hui K; Hapke E
    Harm Reduct J; 2019 Jul; 16(1):43. PubMed ID: 31288862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motives and Side-Effects of Microdosing With Psychedelics Among Users.
    Hutten NRPW; Mason NL; Dolder PC; Kuypers KPC
    Int J Neuropsychopharmacol; 2019 Jul; 22(7):426-434. PubMed ID: 31152167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.